

#### Supplemental figures and figure legends


Supplementary Figure 1: Regional association plots of HLA SNP associations with primary phenotypes of peanut specific IgG4 (psIgG4), peanut specific IgE (psIgE) and PA in LEAP consumption and avoidance group at 60 months. Red line shows statistically significant association (P=5.13x10-6, after correcting for 9,742 SNPs in the HLA region). Purple diamonds are the SNPs with lowest P-value for each trait.




**Supplementary Figure 2:** Regional association plots of HLA SNP associations with psIgG4 19 showing **[A]** the primary analysis and **[B]** a conditional analysis where SNPs are tested 20 conditioned on the primary variant rs17612852.



**Supplementary Figure 3:** Regional association plots the HLA Class II region. Top row is the 53 association for log10(psIgG4) and log10(Ara h 2) at 60 months. Rows 2-4 are the eQTLs for 54 the same variants for each of 7 genes expressed in the CD4 T cells. The color of each dot 55 represents its correlation to the peak variant rs17612852 (see r2 legend). The purple diamond 56 represents index variant rs17612852, and the blue box is drawn around HLA-DQA1\*01:02. 57 Red dashed line represents Bonferroni thresholds for the trait associations (p<5.13x10<sup>-6</sup>) and 58 eQTLs (p<3.71x10<sup>-6</sup>).




Supplementary Figure 4: Co-localization analysis between the eQTLs for Class II gene expression (HLA-DQA1 and HLA-DQB1) in CD4 T cells and phenotype associations noted for psIgG4. **Panel A** shows the correlation between the p-values noted for the IgG4 associations and eQTLs for each variant for DQA1 (upper) and DQB1 (lower); the blue diamond is sentinel variant rs17612852. The p-value for the IgG4 association is same in the upper and lower plot, but the eQTL p-values differ. It is noted that for DQA1 (upper), the strongest IgG4 SNP, is not a perfect match for the strongest DQA1 gene eQTL; there are several SNPs with stronger regulatory evidence for gene expression (green oval). In contrast for DQB1, the strongest eQTL SNP perfectly matches the strongest IgG4 SNP rs17612852. Panel B is the SuSie fine-mapping for HLA-DOB1 eQTLs showing a single credible set (CS1) with the sentinel variant rs17612852 identified as the target variant. This is additional evidence that there is perfect co-localization between the IgG4 association and regulatory evidence for HLA-DQB1. Also marked is HLA-DQA1\*01:02 which is not identified in a credible set for HLA-DQB1 expression. 




97 Supplementary Figure 5: Associations of HLA-DQA1\*01:02 and *MALT1* (rs57265082) with
98 psIgG4 and psIgE over time. Figures show the -log(P-value) across the visits, and tables have
99 the effect sizes for the variants for log10(psIgE) and log10(psIgG4). The effect sizes represent
100 the difference in the mean between the two groups (carrier vs. non-carrier) on the log10 scale.
101

[A]




[B] MALT1 (rs57265082) / LEAP Avoidance Group




Supplementary Figure 6: Associations of HLA-DQA1\*01:02 and *MALT1* (rs57265082) with psIgG4 and psIgE over time in Consumption and Avoidance groups. Figures show the -log(Pvalue) across the visits, and tables have the effect sizes for the variants for log10(psIgE) and log10(psIgG4). The effect sizes represent the difference in the mean between the two groups (carrier vs. non-carrier) on the log10 scale.

113








115

[B]


**Supplementary Figure 7:** Relative distribution of psIgG4 and psIgE, and IgG4 and IgE to peanut components by carrier status at HLA-DQA1\*01:02 and *MALT1* SNP rs57265082, across all visits. Unadjusted mean values of the phenotypes stratified by variants carrier status at each assessment and by treatment group assignment are shown with bootstrapped 95% confidence intervals and P-values. Dashed line at 60 months of age depicts the end of LEAP trial at which all participants avoided peanut consumption for 12 months.


- 122
- 123





138 Supplemental Figure 8: Association of mean linear epitope bindings with genotypes at 60 139 months vs. baseline in peanut exposure groups subdivided by outcome. In [A and B] bars represent the changes in expansion of z-scores of mean bindings per peanut component from 140 baseline to visit 60. Stars indicate significance in differences between the two 141 genotypes. [A] ses-IgG4 expansion by HLA-DQA1\*01:02 genotype. [B] ses-IgE expansion 142 by MALT1 genotype status; error-bars in all panels represent confidence intervals: 143 144 Mean±95%CI; sample size within each group is represented in brackets.















Supplementary Figure 9: Canonical Correlation Analysis (CCA) evaluating the association of the linear epitopes in ses-IgG4 belonging to groups related to Ara h 1, h 2 and h 3 with HLA-DQA1\*01:02 and ses-IgE Ara h 1, h 2 and h 3 with MALT1 rs57265082 over time in the Consumption and Avoidance groups. Dashed lines indicate significance level at p=0.05. 



### Supplementary Tables:

**Table S1:** Association analysis results for all 38 HLA alleles with primary phenotypes of peanut allergy, psIgG4 and psIgE at 60 months. Results with p<0.05 are bolded. 

	А	llele Freq (%	<b>(</b> 0)		PA		psl	IgE		psIgG4				
	Full Group	Avoider s	Consum ers	A	voiders	Av	oiders	Cor	sumers	Av	oiders	Con	sumers	
Gene*Allele	(N=542)	(N=275)	(N=267)	OR	<b>P-Value</b>	Beta	<b>P-Value</b>	Beta	<b>P-Value</b>	Beta	<b>P-Value</b>	Beta	P-Value	
HLA-A*03:01	11.41%	11.76%	11.04%	0.98	9.52E-01	-0.192	2.52E-01	-0.104	4.65E-01	0.018	8.23E-01	-0.061	5.75E-01	
HLA-A*01:01	14.48%	15.10%	13.86%	1.62	2.05E-01	0.198	2.21E-01	0.029	8.29E-01	-0.008	9.20E-01	-0.102	3.17E-01	
HLA-A*24:02	9.42%	7.45%	11.45%	0.39	1.42E-01	-0.075	7.19E-01	0.060	6.82E-01	-0.042	6.82E-01	0.183	9.63E-02	
HLA-A*11:01	5.95%	4.71%	7.23%	1.82	2.69E-01	0.308	2.26E-01	-0.070	6.94E-01	0.243	5.48E-02	0.070	6.09E-01	
HLA-A*02:01	27.38%	28.63%	26.10%	0.46	3.35E-02	-0.371	9.73E-03	0.025	8.29E-01	-0.175	1.24E-02	0.051	5.68E-01	
HLA-B*07:02	10.39%	11.15%	9.60%	0.79	5.87E-01	-0.323	6.51E-02	-0.291	4.65E-02	-0.016	8.51E-01	0.159	1.61E-01	
HLA-B*08:01	10.20%	11.92%	8.40%	1.72	1.61E-01	0.255	1.40E-01	-0.059	7.14E-01	0.072	4.04E-01	-0.203	1.06E-01	
HLA-B*44:02	9.12%	9.04%	9.20%	1.37	4.67E-01	0.163	3.93E-01	-0.184	2.26E-01	-0.066	4.83E-01	-0.064	5.88E-01	
HLA-B*44:03	6.27%	6.92%	5.60%	1.04	9.42E-01	0.135	5.16E-01	-0.053	7.64E-01	0.194	6.00E-02	-0.075	5.86E-01	
HLA-B*40:01	5.29%	4.81%	5.80%	0.32	1.47E-01	-0.043	8.61E-01	-0.031	8.67E-01	-0.052	6.63E-01	0.024	8.68E-01	
HLA-C*07:02	11.22%	11.05%	11.39%	0.98	9.60E-01	-0.242	1.66E-01	-0.303	2.80E-02	-0.053	5.37E-01	0.025	8.14E-01	
HLA-C*07:01	13.83%	15.89%	11.78%	1.54	2.39E-01	0.175	2.74E-01	0.149	2.85E-01	0.061	4.39E-01	0.032	7.58E-01	
HLA-C*06:02	8.90%	7.75%	10.04%	2.23	5.68E-02	0.383	6.16E-02	-0.121	4.00E-01	0.029	7.70E-01	-0.164	1.31E-01	
HLA-C*04:01	10.64%	11.05%	10.23%	0.59	2.91E-01	-0.101	5.89E-01	-0.113	4.40E-01	0.083	3.63E-01	0.079	4.81E-01	
HLA-C*16:01	5.61%	6.01%	5.21%	0.96	9.34E-01	0.068	7.62E-01	0.166	3.86E-01	0.026	8.12E-01	0.048	7.41E-01	
HLA-C*03:04	7.45%	7.17%	7.72%	0.39	1.41E-01	-0.176	3.91E-01	0.126	4.36E-01	-0.092	3.59E-01	0.044	7.17E-01	
HLA-C*05:01	8.22%	8.91%	7.53%	0.94	8.92E-01	0.020	9.19E-01	-0.105	5.16E-01	-0.068	4.73E-01	0.017	8.89E-01	
HLA-C*12:03	5.03%	5.62%	4.44%	0.36	1.90E-01	-0.325	1.78E-01	-0.097	6.48E-01	-0.086	4.68E-01	-0.057	7.21E-01	
HLA-G*01:01	77.73%	79.42%	75.99%	0.43	1.64E-01	-0.650	3.61E-02	0.163	4.43E-01	-0.380	1.57E-02	-0.021	8.96E-01	
HLA-G*01:04	13.18%	12.88%	13.49%	0.96	9.28E-01	0.009	9.63E-01	-0.073	5.94E-01	0.108	2.44E-01	0.061	5.61E-01	
HLA-L*01:01	76.04%	76.95%	75.10%	0.90	8.52E-01	0.101	7.11E-01	-0.249	2.40E-01	-0.128	3.43E-01	-0.203	2.14E-01	
HLA-L*01:02	23.96%	23.05%	24.90%	0.64	2.32E-01	0.025	8.72E-01	0.099	3.91E-01	-0.008	9.12E-01	0.132	1.41E-01	
HLA-DQA1*03:01	9.18%	7.71%	10.70%	0.94	9.06E-01	-0.166	4.10E-01	-0.231	9.39E-02	-0.170	9.09E-02	-0.067	5.21E-01	
HLA-DQA1*05:05	12.43%	9.96%	14.98%	0.90	8.12E-01	0.024	8.98E-01	0.017	8.92E-01	0.067	4.67E-01	0.031	7.50E-01	
HLA-DQA1*01:02	16.92%	18.42%	15.37%	1.99	4.37E-02	-0.095	5.22E-01	0.057	6.46E-01	-0.071	3.40E-01	0.342	2.21E-04	
HLA-DQA1*05:01	12.72%	13.35%	12.06%	1.29	4.95E-01	0.082	6.13E-01	-0.101	4.63E-01	0.020	8.03E-01	-0.250	1.58E-02	
HLA-DQA1*01:01	10.04%	10.15%	9.92%	0.56	2.63E-01	-0.121	5.02E-01	0.010	9.46E-01	-0.022	8.11E-01	-0.034	7.52E-01	
HLA-DQA1*01:03	6.50%	5.83%	7.20%	0.76	6.37E-01	0.092	6.76E-01	0.141	3.81E-01	0.099	3.69E-01	0.278	2.15E-02	
HLA-DQA1*02:01	14.24%	15.60%	12.84%	0.92	8.34E-01	0.142	3.60E-01	0.066	6.12E-01	0.069	3.76E-01	-0.127	1.95E-01	
HLA-DQA1*03:03	8.60%	8.27%	8.95%	0.94	8.96E-01	0.113	5.53E-01	-0.052	7.33E-01	0.006	9.49E-01	-0.197	8.90E-02	
HLA-DQB1*03:01	18.83%	15.79%	21.98%	0.75	4.81E-01	0.106	5.02E-01	0.157	1.67E-01	0.012	8.79E-01	-0.007	9.39E-01	
HLA-DQB1*03:02	11.38%	9.59%	13.23%	0.85	7.17E-01	-0.144	4.27E-01	-0.284	2.61E-02	-0.110	2.27E-01	-0.140	1.51E-01	
HLA-DQB1*02:01	11.85%	12.78%	10.89%	1.23	5.86E-01	0.109	5.07E-01	-0.092	5.12E-01	0.019	8.19E-01	-0.263	1.31E-02	
HLA-DQB1*05:01	11.19%	11.09%	11.28%	0.43	9.92E-02	-0.100	5.72E-01	0.109	4.18E-01	-0.003	9.70E-01	0.014	8.88E-01	
HLA-DQB1*02:02	11.66%	13.16%	10.12%	0.90	7.99E-01	0.200	2.20E-01	0.198	1.65E-01	0.097	2.36E-01	-0.157	1.48E-01	
HLA-DQB1*06:02	10.99%	13.16%	8.75%	1.96	6.18E-02	-0.092	5.76E-01	-0.032	8.23E-01	-0.035	6.67E-01	0.250	2.16E-02	
HLA-DPB2*03:01	65.75%	64.57%	66.94%	0.84	7.21E-01	-0.221	2.57E-01	-0.244	1.22E-01	0.009	9.22E-01	-0.173	1.48E-01	
HLA-DPB2*01:01	34.25%	35.43%	33.06%	0.74	4.31E-01	0.067	6.48E-01	-0.079	5.00E-01	0.028	6.96E-01	-0.017	8.51E-01	

## **Table S2:** Evaluating the association between psIgG4 and HLA-DQA1\*01:01 accounting for PA. Results with p<0.05 are bolded. 177

### 

			1	DIDERS			CONSUMERS									
	ORIGINAL MODEL		SUB	LUDING JECTS TH PA		AS A ARIATE	-	GINAL ODEL	SUBJEC	LUDING CTS WITH PA		AS A ARIATE				
	Ν	=275	N	=227	Ν	=275	Ν	N=267		N=267 N=266		=266	N	=267		
Model components	Beta	P-Value	Beta	P-Value	Beta	P-Value	Beta	P-Value	Beta	P-Value	Beta	P-Value				
Age	0.023	2.57E-01	0.034	1.33E-01	0.025	2.07E-01	0.027	2.54E-01	0.025	2.81E-01	0.025	2.81E-01				
Sex	0.061	3.98E-01	0.038	6.24E-01	0.053	4.59E-01	0.212	1.01E-02	0.207	1.20E-02	0.207	1.20E-02				
PC1	-1.255	1.29E-01	-1.517	1.05E-01	-1.020	2.14E-01	-1.241	1.95E-01	-1.258	1.90E-01	-1.258	1.90E-01				
PC2	-3.124	1.93E-03	-2.156	8.73E-02	-2.927	3.36E-03	-1.204	1.54E-01	-1.185	1.61E-01	-1.185	1.61E-01				
PC3	-0.560	5.36E-01	0.365	7.39E-01	-0.630	4.81E-01	0.965	2.78E-01	0.957	2.82E-01	0.957	2.82E-01				
PC4	1.821	1.73E-02	0.989	2.58E-01	1.789	1.80E-02	-0.356	7.20E-01	-0.376	7.05E-01	-0.376	7.05E-01				
PC5	0.480	5.35E-01	0.424	6.19E-01	0.627	4.14E-01	0.451	6.33E-01	0.468	6.21E-01	0.468	6.21E-01				
Peanut Allergy	-	-	-	-	0.237	9.87E-03	-	-	-	-	-0.506	4.31E-01				
HLA-DQA1*01:02	-0.071	3.40E-01	-0.115	1.66E-01	-0.095	2.03E-01	0.342	2.21E-04	0.339	2.58E-04	0.339	2.58E-04				

191	Table S3:	Association	analysis	results	for	HLA	alleles	with	primary	phenotypes	of peanu	ıt
-----	-----------	-------------	----------	---------	-----	-----	---------	------	---------	------------	----------	----

allergy, psIgG4 and psIgE at 60 months in participants of self-reported European ethnicity. Results with p<0.05 are bolded. 

	Allel	le Frequency	v (%)	PA psIgE					psI	gG4			
Alleles	Full Group	Avoider s	Consum ers	Avoide	ers (N=211)	Avoide	rs (N=211)		Consumers (N=191)		rs (N=211)		isumers (=191)
	(N=402)	(N=211)	(N=191)	OR	P-Value	Beta	P-Value	Beta	P-Value	Beta	P-Value	Beta	P-Value
HLA-A*02:01	30.71%	31.91%	29.40%	0.55	1.65E-01	-0.228	1.50E-01	0.187	1.13E-01	-0.165	2.99E-02	0.084	4.11E-01
HLA-B*07:02	11.68%	12.63%	10.66%	1.06	9.02E-01	-0.190	3.17E-01	-0.121	4.09E-01	0.034	7.09E-01	0.196	1.19E-01
HLA-C*07:02	11.23%	11.36%	11.08%	1.39	5.12E-01	-0.208	2.91E-01	-0.160	2.78E-01	-0.005	9.60E-01	0.161	2.03E-01
HLA-G*01:01	83.29%	84.50%	81.94%	1.00	4.58E-01	-0.211	6.54E-01	0.234	4.25E-01	-0.891	1.00E-04	-0.416	1.07E-01
HLA-DQA1*01:02	14.95%	15.76%	14.05%	3.54	3.63E-03	0.012	9.44E-01	0.023	8.64E-01	-0.060	4.70E-01	0.395	3.34E-04
HLA-DQA1*05:01	13.53%	14.29%	12.70%	1.81	1.90E-01	0.147	4.19E-01	0.020	8.87E-01	0.041	6.44E-01	-0.172	1.58E-01
HLA-DQA1*01:03	6.06%	5.91%	6.22%	0.59	5.00E-01	0.152	5.39E-01	0.181	3.07E-01	0.211	8.05E-02	0.382	1.07E-02
HLA-DQB1*03:02	12.72%	10.29%	15.41%	0.82	7.08E-01	-0.202	3.17E-01	-0.234	6.42E-02	-0.182	6.59E-02	-0.154	1.55E-01
HLA-DQB1*02:01	12.72%	13.73%	11.62%	1.73	2.21E-01	0.165	3.77E-01	-0.025	8.63E-01	0.046	6.15E-01	-0.208	9.03E-02
HLA-DQB1*06:02	10.54%	12.01%	8.92%	3.02	1.14E-02	-0.076	6.84E-01	-0.038	7.96E-01	-0.032	7.27E-01	0.333	8.32E-03
HLA-DQB1*06:02	10.54%	12.01%	8.92%	3.02	1.14E-02	-0.076	6.84E-01	-0.038	7.96E-01	-0.032	7.27E-01	0.333	8.32E-0

**Table S4:** Association of HLA haplotypes with frequency  $\geq=5\%$  with primary phenotypes of peanut allergy, psIgG4 and psIgE at 60 months. Results with p<0.05 are bolded. 

Haplotypes	Hapl	otype Freq	(%)		PA psIgE			gE		psIgG4					
	Full Group	Avoide rs	Consu mers	Av	oiders	Av	oiders	Con	sumers	Av	oiders	Con	sumers		
	Group	13	mers	OR	P-Value	Beta	P-Value	Beta	P-Value	Beta	P-Value	Beta	P-Value		
HLA-DQA1~HLA-DQB1															
DQA1*05:01~DQB1*02:01	12.00%	12.84%	11.13%	1.28	5.26E-01	0.143	3.92E-01	-0.143	3.14E-01	0.036	6.73E-01	-0.305	4.31E-0.		
DQA1*05:05~DQB1*03:01	11.51%	8.95%	14.17%	0.46	1.75E-01	-0.005	9.81E-01	0.117	3.60E-01	0.098	3.20E-01	0.021	8.33E-0		
DQA1*01:02~DQB1*06:02	11.41%	13.62%	9.11%	1.96	6.35E-02	-0.089	5.89E-01	-0.054	7.10E-01	-0.036	6.67E-01	0.242	2.69E-02		
DQA1*02:01~DQB1*02:02	11.21%	12.84%	9.51%	1.06	8.79E-01	0.276	1.02E-01	0.167	2.57E-01	0.113	1.84E-01	-0.137	2.22E-0		
DQA1*01:01~DQB1*05:01	10.02%	9.73%	10.32%	0.58	2.96E-01	-0.101	5.85E-01	0.046	7.48E-01	-0.023	8.09E-01	-0.019	8.61E-0		
DQA1*03:01~DQB1*03:02	9.33%	7.78%	10.93%	0.96	9.32E-01	-0.160	4.33E-01	-0.213	1.21E-01	-0.169	1.02E-01	-0.056	5.91E-0		
DQA1*03:03~DQB1*03:01	6.35%	6.03%	6.68%	1.28	6.23E-01	0.272	2.14E-01	0.088	6.11E-01	0.009	9.32E-01	-0.055	6.79E-0		
HLA-DQA1~HLA- DQB1~HLA-DRB1															
DQA1*05:01~DQB1*02:01 ~DRB1*03:01 DQA1*02:01~DQB1*02:02	12.67%	14.44%	10.80%	0.93	8.70E-01	-0.017	9.31E-01	0.064	7.05E-01	-0.021	8.35E-01	-0.262	4.73E-0		
~DRB1*07:01	12.40%	14.17%	10.51%	0.92	8.63E-01	0.268	1.71E-01	0.145	3.77E-01	0.164	1.07E-01	-0.223	8.21E-0		
DQA1*01:02~DQB1*06:02 ~DRB1*15:01 DQA1*01:01~DQB1*05:01	10.06%	11.76%	8.24%	2.16	8.23E-02	-0.173	3.91E-01	-0.018	9.18E-01	-0.028	7.86E-01	0.409	2.94E-0		
~DRB1*01:01 DQA1*03:03~DQB1*03:01	9.09%	7.75%	10.51%	0.86	7.99E-01	-0.132	5.78E-01	-0.106	5.21E-01	-0.087	4.80E-01	-0.039	7.65E-0		
~DRB1*04:01	6.20%	6.42%	5.97%	1.99	2.05E-01	0.410	1.05E-01	0.030	8.84E-01	0.047	7.20E-01	-0.026	8.74E-0		
210															
211															
212															
213															
214															
215															
216															
217															

- Table S5. Association of HLA Class II gene expression in CD4 T cells with rs17612852 and
- DQA1\*01:02 genotypes. An additive model was used for rs17612852 SNP genotype, and a dominant model was used for HLA-DQA1\*01:02 carrier status.

Gene	Variant	Minor allele	Beta*	P-value*
DRA	rs17612852	G	0.393	2.36E-02
	DQA1*01:02	carrier	0.388	9.78E-02
DRB5	rs17612852	G	0.466	3.79E-02
	DQA1*01:02	carrier	0.821	4.53E-03
DRB1	rs17612852	G	0.414	3.66E-03
	DQA1*01:02	carrier	0.534	5.00E-03
DQA1	rs17612852	G	1.303	1.66E-07
	DQA1*01:02	carrier	1.182	7.72E-04
DQB1	rs17612852	G	1.567	8.34E-13
	DQA1*01:02	carrier	1.396	1.27E-05
DPA1	rs17612852	G	0.418	7.08E-03
	DQA1*01:02	carrier	0.457	3.30E-02
DPB1	rs17612852	G	-0.035	7.90E-01
	DQA1*01:02	carrier	-0.007	9.68E-01
near regressio	n adjusted for sex, rad	ce, allergic stat	us, treatment gr	roup, and cell v



**Table S6:** Sample sizes for each phenotype by timepoint from the total of 267 Consumers and

244 275 avoiders.

Phenotypes	Consumers	Avoiders								
	vo	)	V1	2	V3	0	V60		V	72
psIgE	265	274	262	273	260	264	255	266	214	238
Ara h 1 IgE	260	271	260	273	259	263	251	261	209	231
Ara h 2 IgE	260	271	260	273	259	263	251	261	209	230
Ara h 3 IgE	260	271	260	273	259	263	251	261	209	230
Ara h 8 IgE	260	270	260	273	259	263	250	261	208	230
Ara h 9 IgE	260	271	259	272	258	262	251	261	207	230
psIgG4	260	269	257	273	259	264	254	265	213	238
Ara h 1 IgG4	241	241	231	238	234	231	249	254	152	214
Ara h 2 IgG4	241	241	231	238	234	231	249	254	152	214
Ara h 3 IgG4	241	241	231	238	234	231	249	254	152	214
Ara h 8 IgG4	241	241	231	238	234	231	249	254	152	214
Ara h 9 IgG4	241	241	231	238	234	231	249	254	152	214

Table S7: Linear regression models for psIgG4 to determine the direct vs. indirect effects of MALT1 (rs57265082) and HLA-DQA1\*01:02. Five linear regression models (M1-M5) were run on log10(psIgG4), all of which included covariates of age, sex and 5PCs. In all models rs57265082 and HLA-DQA1\*01:02 were coded as dominant (i.e. carrier vs. non-carrier); the minor heterozygote and homozygote for rs57265082 were combined to facilitate the interactions being tested with peanut exposure. Exact variables in each model are listed as Model components in the table. M1 was run in the full group of avoiders and consumers combined, and included both genetic variants, log10(psIgE), peanut consumption and interactions with peanut consumption. Models M2-M3 were performed in the Avoiders alone to see how much of the effect of each genetic variant on psIgG4 was mediated through psIgE. Models M4-M5 were performed in Consumers alone to see how much of the effect of each genetic variant on psIgG4 was mediated through psIgE.

	FULI	GROUP N=	=542		A	VOIDE	RS N=275				CONS	UM	MERS N=267		
Model components	Est	M1 P-value		Est	M2 P-value		Est	M3 P-value		Est	M4 P-value		Est	M5 P-value	
Age	0.032	2.30E-02	*	0.026	1.99E-01		0.022	2.51E-01		0.024	3.07E-01		0.039	6.20E-02	
Sex	0.062	2.11E-01		0.059	4.07E-01		0.019	7.75E-01		0.188	2.13E-02	*	0.103	1.61E-01	
PC1	-0.151	8.09E-01		-1.456	8.31E-02		-0.520	5.18E-01		-1.556	1.52E-01		0.181	8.56E-01	
PC2	-1.179	4.69E-02	*	-2.585	8.81E-03	**	-2.061	2.69E-02	*	-1.780	4.28E-02	*	-0.740	3.52E-01	
PC3	0.104	8.54E-01		-0.257	7.71E-01		-0.163	8.45E-01		0.652	4.58E-01		0.144	8.55E-01	
PC4	0.734	1.83E-01		1.624	2.99E-02	*	1.450	3.95E-02	*	-0.651	5.08E-01		-0.113	8.98E-01	
PC5	0.949	9.65E-02		0.623	4.17E-01		0.678	3.49E-01		1.483	1.51E-01		1.296	1.60E-01	
HLA-DQA1*01:02	-0.036	5.65E-01		-0.076	2.44E-01		-0.040	5.10E-01		0.250	2.64E-03	*	0.244	1.05E-03	*
MALT1 (rs57265082)	0.249	2.72E-02	*	0.420	1.63E-04	***	0.235	3.12E-02	*	-0.313	2.48E-02	*	-0.138	2.76E-01	
Log10(psIgE)	0.180	1.92E-08	***				0.175	3.08E-08	***				0.332	5.50E-13	* * *
Peanut Consumption	0.754	< 2e-16	***												
HLA*Peanut Consumption	0.283	2.44E-03	**												
MALT1*group Peanut Consumption	-0.414	1.00E-02	*												
psIgE*group Peanut Consumption	0.149	3.15E-03	**												

## Signif. codes: '\*\*\*' for < 0.001, '\*\*' for < 0.01, '\*' for < 0.05, and '.' for < 0.1

77 Interaction terms with Peanut Consumption are in bold

Est == Beta estimates of the individual predictor variable in the linear regression models

P-values == p-value of individual predictor variables

287	<b>Table S8A</b> : Model parameter estimates from the mixed linear model in Fig 3A.
288	

Outcome	Term	Estimate	P-value	95% Lower	95% Upper
	Intercept	2.02	4e-322	1.97	2.07
	Treatment Group [Peanut Avoidance]	-0.30	3.00E-47	-0.34	-0.26
Peanut-specific IgG4	Age at Visit (years)	0.14	1.00E-85	0.13	0.15
(log10)	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	-0.05	6.00E-14	-0.06	-0.04
	HLA DQA1 01:02:01:01[Carrier]	0.05	8.50E-03	0.01	0.08
	Treatment Group [Peanut Avoidance]*HLA DQA1 01:02:01:01[Carrier]	-0.06	2.30E-03	-0.09	-0.02
	Intercept	1.60	4e-322	1.57	1.64
	Treatment Group [Peanut Avoidance]	-0.08	5.00E-10	-0.11	-0.06
	Age at Visit (years)	0.03	5.00E-12	0.02	0.04
Ara h 1 IgG4 (log10)	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	-0.02	5.80E-07	-0.03	-0.01
	HLA DQA1 01:02:01:01[Carrier]	0.00	7.90E-01	-0.02	0.03
	Treatment Group [Peanut Avoidance]*HLA DQA1 01:02:01:01[Carrier]	0.00	9.10E-01	-0.02	0.03
	Intercept	1.64	4e-311	1.60	1.68
	Treatment Group [Peanut Avoidance]	-0.22	3.00E-33	-0.26	-0.19
	Age at Visit (years)	0.07	4.00E-30	0.06	0.08
Ara h 2 IgG4 (log10)	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	-0.05	4.00E-20	-0.06	-0.04
	HLA DQA1 01:02:01:01[Carrier]	0.08	2.40E-06	0.05	0.11
	Treatment Group [Peanut Avoidance]*HLA DQA1 01:02:01:01[Carrier]	-0.07	2.70E-05	-0.11	-0.04
	Intercept	2.03	4e-322	1.98	2.07
	Treatment Group [Peanut Avoidance]	-0.18	3.00E-22	-0.21	-0.15
	Age at Visit (years)	0.08	2.00E-35	0.07	0.09
Ara h 3 IgG4 (log10)	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	-0.03	6.20E-06	-0.04	-0.02
	HLA DQA1 01:02:01:01[Carrier]	0.01	4.10E-01	-0.02	0.05
	Treatment Group [Peanut Avoidance]*HLA DQA1 01:02:01:01[Carrier]	0.00	8.40E-01	-0.04	0.03
	Intercept	1.54	4e-322	1.51	1.56
	Treatment Group [Peanut Avoidance]	0.01	2.40E-01	-0.01	0.02
	Age at Visit (years)	0.02	5.40E-08	0.01	0.02
Ara h 8 IgG4 (log10)	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	0.00	1.80E-01	0.00	0.01
	HLA DQA1 01:02:01:01[Carrier]	0.00	7.90E-01	-0.01	0.02
	Treatment Group [Peanut Avoidance]*HLA DQA1 01:02:01:01[Carrier]	0.01	2.30E-01	-0.01	0.02
	Intercept	1.54	4e-322	1.50	1.57
	Treatment Group [Peanut Avoidance]	-0.02	6.50E-02	-0.05	0.00
	Age at Visit (years)	0.04	9.00E-16	0.03	0.05
Ara h 9 IgG4 (log10)	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	-0.01	7.60E-02	-0.02	0.00
	HLA DOA1 01:02:01:01[Carrier]	0.03	1.70E-02	0.01	0.00
	inter by an onotation of camera	0.05	1.701-02	0.01	0.00

# 294 295 **Table S8B:** Model parameter estimates from the mixed linear model in Fig 3B.

295 Outcome	Term	Estimate	P-value	95% Lower	95% Upper
	Intercept	-0.97	8.57E-56	-1.08	-0.86
	Treatment Group [Peanut Avoidance]	0.13	1.33E-02	0.03	0.24
Peanut-Specific IgE	MALT1 Risk Groups (ALL)[Carrier]	0.26	1.35E-06	0.16	0.37
(kU/liter,log10)	Treatment Group [Peanut Avoidance]*MALT1 Risk Groups (ALL)[Carrier]	0.19	4.55E-04	0.08	0.29
	Age at Visit (years)	0.06	2.42E-14	0.04	0.07
	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	-0.01	4.10E-01	-0.02	0.01
	Intercept	-1.47	2.86E-170	-1.55	-1.40
	Treatment Group [Peanut Avoidance]	0.11	4.73E-03	0.03	0.18
Ara h1–Specific IgE	MALT1 Risk Groups (ALL)[Carrier]	0.19	6.92E-07	0.12	0.26
(kU/liter, log10)	Treatment Group [Peanut Avoidance]*MALT1 Risk Groups (ALL)[Carrier]	0.12	2.32E-03	0.04	0.19
	Age at Visit (years)	-0.01	4.16E-02	-0.02	0.00
	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	0.01	5.02E-03	0.00	0.02
	Intercept	-1.47	5.42E-180	-1.55	-1.39
	Treatment Group [Peanut Avoidance]	0.11	2.79E-03	0.04	0.18
Ara h2–Specific IgE	MALT1 Risk Groups (ALL)[Carrier]	0.20	3.01E-08	0.13	0.27
(kU/liter, log10)	Treatment Group [Peanut Avoidance]*MALT1 Risk Groups (ALL)[Carrier]	0.14	1.37E-04	0.07	0.21
	Age at Visit (years)	0.02	8.99E-03	0.00	0.03
	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	0.02	5.63E-03	0.01	0.03
	Intercept	-1.58	9.95E-212	-1.65	-1.51
	Treatment Group [Peanut Avoidance]	0.05	1.69E-01	-0.02	0.11
Ara h3–Specific IgE	MALT1 Risk Groups (ALL)[Carrier]	0.13	1.24E-04	0.06	0.19
(kU/liter, log10)	Treatment Group [Peanut Avoidance]*MALT1 Risk Groups (ALL)[Carrier]	0.11	1.33E-03	0.04	0.17
	Age at Visit (years)	0.01	4.80E-02	0.00	0.02
	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	0.00	7.09E-01	-0.01	0.01
	Intercept	-1.97	2.978e-320	-2.03	-1.90
	Treatment Group [Peanut Avoidance]	0.04	1.90E-01	-0.02	0.09
Ara h8–Specific IgE	MALT1 Risk Groups (ALL)[Carrier]	0.06	2.31E-02	0.01	0.11
(kU/liter, log10)	Treatment Group [Peanut Avoidance]*MALT1 Risk Groups (ALL)[Carrier]	0.08	2.90E-03	0.03	0.13
	Age at Visit (years)	0.09	1.47E-30	0.07	0.10
	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	-0.01	5.40E-02	-0.03	0.00
	Intercept	-1.86	4.2e-322	-1.90	-1.81
	Treatment Group [Peanut Avoidance]	0.01	6.48E-01	-0.03	0.05
Ara h9–Specific IgE	MALT1 Risk Groups (ALL)[Carrier]	0.08	1.32E-04	0.04	0.12
(kU/liter, log10)	Treatment Group [Peanut Avoidance]*MALT1 Risk Groups (ALL)[Carrier]	0.03	2.18E-01	-0.02	0.07
	Age at Visit (years)	0.02	9.08E-12	0.02	0.03
	(Age at Visit (years))*Treatment Group[Peanut Avoidance]	-0.01	8.90E-02	-0.01	0.00

- 300 301 
  **Table S9:** Demographics and clinical outcomes of participants included in epitope analysis.

Demographics	Consumers (N=161)	Avoiders (N=162)
Age at screening (mo), mean (SD)	7.61 (1.78)	7.78 (1.75)
Male sex (N)	52.8% (85)	65.4% (106)
Ethnicity (N)		
White	67% (108)	74% (120)
Black	9% (15)	10% (17)
Mixed	16% (26)	12% (19)
Asian	6% (9)	2% (4)
Chinese, Middle Eastern or other	2% (3)	1% (2)
Outcomes at 60 months		
PA (allergics/non-allergics)	0/161	37/125
psIgE	0.17 [0.13;0.24]	0.23 [0.15;0.34]
Ara h 1 IgE	0.02 [0.02;0.02]	0.04 [0.02;0.05]
Ara h 2 IgE	0.02 [0.02;0.03]	0.05 [0.03;0.07]
Ara h 3 IgE	0.03 [0.02;0.04]	0.03 [0.02;0.04]
Ara h 8 IgE	0.04 [0.03;0.06]	0.04 [0.03;0.05]
Ara h 9 IgE	0.02 [0.02;0.03]	0.02 [0.02;0.02]
psIgG4	1140.74 [903.63;1440.08]	207.70 [168.44;256.11]
Ara h 1 IgG4	73.29 [60.62;88.60]	40.55 [37.46;43.89]
Ara h 2 IgG4	179.49 [137.83;233.74]	41.81 [38.26;45.69]
Ara h 3 IgG4	423.33 [338.60;529.25]	145.79 [118.49;179.39]
Ara h 8 IgG4	41.03 [37.34;45.09]	45.16 [39.47;51.66]
Ara h 9 IgG4	69.11 [55.23;86.47]	52.99 [44.75;62.75]

**Table S10:** HLA associations with psIgG in LEAP consumers at 60 months

	log10(psIgG4)		log10(psIgG)		log10(psIgG) adjusted for psIgG4		log10(psIgG) adjusted for Ara h2 IgG4	
	Beta	P-value	Beta	P-value	Beta	P-value	Beta	P-value
HLA-DQA1*01:02	0.342	2.21E-04	0.111	3.09E-02	-0.017	0.67	-0.018	0.69
rs17612852	0.342	5.80E-07	0.142	1.63E-04	0.018	0.54	0.049	0.15

Table S11: Association of peanut allergy (PA) associated HLA variants from previous studies
with PA in LEAP peanut avoidance group and psIgG4 in LEAP peanut consumption group.
[A] PA associated HLA SNPs, [B] PA associated imputed HLA alleles. LD for SNPs was
calculated with respect to rs17612852 and for alleles with HLA-DQA1\*01:02. Peak variants
(rs17612852 and HLA-DQA1\*01:02) in the LEAP study are bolded.

Previous studies					LEAP study							
							Association with Peanut Allergy in peanut avoidance group (N=275)		Association with psIgG4 in peanut consumption group (N=267)			
		OR	Р	Gene/Nearest gene	Allel es	MA F*	OR	Р	Beta	Р	R- sq	D'
[A] HLA SNP	's											
Hong et al. (1)	rs7192 rs9275596 rs33980016	1.7 1.7 NA	5.50E-08 6.80E-10 3.20E-11	HLA-DRA HLA-DQB1 HLA-DQA2 HLA-DQB1	T/G C/T	0.35 0.32	1.55 1.55 -	5.23E-02 8.37E-02	0.179 0.135	4.99E-03 4.04E-02	0.21 0.36	0.62 0.75
Marenholz et al. (2)	rs9273440	0.66	6.60E-07	HLA-DQB1	-	-	-	-	-	-	-	-
Asai et al.(3)	rs1049213 rs3134976 rs3134994 rs3135006 rs3134995 rs1049053 rs1049025 <b>rs17612852</b> rs9275596 rs1612904 rs3135002 rs7774434 rs1049056 rs4947344	NA 2.11 2.11 2.1 2.08 2.08 2.08 2.08 1.99 1.76 1.76 1.97 0.58 0.47 1.71	1.82E-11 2.15E-10 2.45E-10 3.17E-10 4.66E-10 4.66E-10 4.66E-10 1.86E-09 1.04E-07 1.36E-07 1.61E-07 2.22E-07 2.75E-07 4.19E-07	HLA-DQB1 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQB1 HLA-DQB1 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQA2 HLA-DQB1 HLA-DQA2	- A/C T/C T/C T/C C/T A/G C/T C/A - C/T - T/C	0.19 0.19 0.20 0.19 0.20 0.20 0.20 0.20 0.23 0.32 0.32 0.32	- 1.57 1.57 1.61 1.67 1.68 1.61 1.60 1.55 1.55 - 0.68 - 1.71	1.23E-01 1.23E-01 1.04E-01 8.31E-02 7.71E-02 1.04E-01 1.04E-01 <b>3.27E-01</b> 8.37E-02 8.37E-02 - 1.08E-01	0.264 0.264 0.285 0.264 0.285 0.297 0.282 0.135 0.135 0.135 0.128	5.46E-04 5.46E-04 1.75E-04 5.46E-04 1.21E-04 1.21E-04 2.22E-04 <b>5.80E-07</b> 4.04E-02 3.80E-02 	- 0.76 0.76 0.79 0.75 0.78 0.80 0.79 <b>ref</b> 0.36 0.37 - 0.11	- 0.98 0.98 0.98 0.98 0.99 0.99 0.99 ref 0.75 0.76 - 0.73 - 0.78
	rs1794275 rs7767167	0.51 1.95	8.22E-07 1.12E-07	HLA-DQB1 HLA-DQA2 HLA-DQB2 HLA-DOB	A/G G/A	0.18 0.11	0.73 1.67	3.08E-01 1.03E-01	0.110 0.130	1.49E-01 2.30E-01	0.04 0.14	0.76 0.61
[B] HLA Alle	les											
Hong et al.	HLA-DQA1*01:02	NA	2.70E-08	HLA-DQA1	-	0.17	1.99	4.37E-02	0.342	2.21E-04	ref	ref
(1)	HLA-DQB1*06 HLA-DQB1*06 HLA-DPB1*03 HLA-DQA1*02 HLA-DRB1*15 HLA-DRB1*07	NA 2.26 3.23 0.36 2.15 0.34	5.40E-09 1.20E-03 4.25E-03 1.48E-02 1.60E-02 1.68E-02	HLA-DQB1 HLA-DQB1 HLA-DPB1 HLA-DQA1 HLA-DRB1 HLA-DRB1	- - - -	- - - -		- - - -	- - - -	- - - -	- - - -	- - - -
Martino et al. ( <i>4</i> )	HLA-DRB1*07 HLA-DPB1*03:01 HLA-DQA1*02:01 HLA-DRB1*07:01 HLA-DQB1*06:02 HLA-DQA1*01:02	0.34 3.23 0.36 0.34 2.11 <b>1.81</b>	1.68E-02 4.25E-02 1.48E-02 1.68E-02 1.72E-02 1.75E-02	HLA-DRB1 HLA-DPB1 HLA-DQA1 HLA-DRB1 HLA-DQB1 HLA-DQA1		- 0.14 - 0.11 <b>0.17</b>	- 0.92 - 1.96 <b>1.99</b>	- 8.34E-01 - 6.18E-02 4.37E-02	0.127 0.250 0.342	1.95E-01 2.16E-02 2.21E-04	- 0.03 - 0.02 <b>ref</b>	- 1.00 - 1.00 <b>ref</b>